Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event and live webcast on December 11, 2023, during the 65th American Society of Hematology Annual Meeting. The event will feature new data for the axatilimab and revumenib programs, and key opinion leaders from renowned institutions.

WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023, at 7:00 a.m. PT / 10:00 a.m. ET during the 65^th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

The event will include new data for both the axatilimab and revumenib programs, and members of the Syndax management team will be joined by the following key opinion leaders:

• Daniel Wolff, M.D., Professor of Hematology, Department of Internal Medicine III of the University of Regensburg
• Eytan M. Stein, M.D., Chief, Program for Drug Development in Leukemia, Department of Medicine, Memorial Sloan Kettering Cancer Center
• Ghayas C. Issa, M.D., Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
• Joshua F. Zeidner, M.D., Associate Professor of Medicine, Chief, Leukemia Research, University of North Carolina, Lineberger Comprehensive Cancer Center
• Neerav N. Shukla, M.D., Chief, Pediatric Translational Medicine Service, Memorial Sloan Kettering Cancer Center

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website or directly through the meeting link here. 

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-host-investor-event-to-discuss-axatilimab-and-revumenib-data-updates-at-65th-ash-annual-meeting-302003796.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals host the investor event and live webcast?

Syndax Pharmaceuticals will host the event on December 11, 2023, during the 65th American Society of Hematology Annual Meeting.

What programs will be featured at the event?

The event will include new data for both the axatilimab and revumenib programs.

Who will be joining the Syndax management team at the event?

Key opinion leaders from renowned institutions such as the University of Regensburg, Memorial Sloan Kettering Cancer Center, and The University of Texas MD Anderson Cancer Center will be joining the Syndax management team at the event.

How can I access the live webcast and accompanying slides?

The live audio webcast and slides may be accessed through the Events & Presentations page in the Investors section of the Company's website or directly through the meeting link provided.

Where can I find a replay of the conference call or webcast?

A replay will be available on the Investors section of the Company's website at www.syndax.com for a limited time for those unable to participate in the conference call or webcast.